(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) rose by a staggering 10.02% to $28.88 at 12:08 EST on Thursday, following the last session’s downward trend. NASDAQ is rising 1.34% to $12,088.78, after three consecutive sessions in a row of losses. This seems, so far, an all-around positive trend exchanging session today.
Arcturus Therapeutics’s last close was $26.25, 16.43% below its 52-week high of $31.41.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $0.33.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 87.52. Meaning, the purchaser of the share is investing $87.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.46%.
Yearly Top and Bottom Value
Arcturus Therapeutics’s stock is valued at $28.88 at 12:08 EST, below its 52-week high of $31.41 and way higher than its 52-week low of $11.70.
More news about Arcturus Therapeutics (ARCT).
